Medical Science Liaison, Endocrinology – New Jersey Region

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates must possess a clinical science degree with an advanced degree in medical science (MD, PhD, PharmD, NP, PA) and at least 7 years of MSL experience, preferably with therapeutic area expertise. A strong business acumen, excellent project management skills, and proven effective interpersonal and communication skills are required. Applicants must be currently authorized to work in the United States and maintain a valid driving record.

Responsibilities

The Medical Science Liaison will engage in clinically meaningful scientific discussions with thought leaders and healthcare professionals to build knowledge and advocacy for Cushing's syndrome and Corcept's products. Responsibilities include providing scientific presentations and educational programs, developing and maintaining relationships with thought leaders, supporting Corcept products through communication and education, and responding to medical inquiries. The MSL will also generate scientific content, attend medical conferences, critically review scientific literature, capture and report insights from the medical community, and support clinical trials and other scientific initiatives. Approximately 70% travel is required.

Skills

Endocrinology

Cortisol Modulators

Glucocorticoid Receptor

Cushing's Syndrome

Medical Affairs

Scientific Communication

Clinical Acumen

Thought Leader Engagement

HCP Education

Medical Inquiries

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free